Xenetic Biosciences (XBIO) Receivables (2012 - 2017)
Xenetic Biosciences' (XBIO) quarterly Receivables came in at $42500.0 in Q3 2017, down 98.58% on a QoQ basis from $3.0 million in Q4 2016.
Xenetic Biosciences (XBIO) Receivables (2012 - 2017) Analysis & Trends
Xenetic Biosciences (XBIO) has 6 years of Receivables data on file, last reported at $42500.0 in Q3 2017.
- Quarterly Receivables changed N/A year-over-year to $42500.0 in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $42500.0 (changed N/A YoY) and the FY2016 annual result came in at $3.0 million, changed N/A from the prior year.
- Receivables retreated to $42500.0 in Q3 2017, from $3.0 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $3.0 million in Q4 2016 to a low of $1722.0 in Q2 2015.
- A 5-year average of $331293.6 and a median of $62229.0 in 2013 frame the typical range for Receivables.
- Annual changes were most pronounced in 2013 — Receivables increased 20.34% — and 2015, when it plunged 99.06%.
- Tracing XBIO's Receivables over 5 years: stood at $4597.0 in 2013, then surged by 2418.49% to $115775.0 in 2014, then slumped by 98.51% to $1722.0 in 2015, then jumped by 174116.03% to $3.0 million in 2016, then sank by 98.58% to $42500.0 in 2017.
- The last three Receivables figures came in at $42500.0 (Q3 2017), $3.0 million (Q4 2016), and $1722.0 (Q2 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Xenetic Biosciences | 7.59 Mn | 1.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 42,500.00 |
| Dec 31, 2016 | 3.00 Mn |
| Jun 30, 2015 | 1,722.00 |
| Mar 31, 2015 | 81,090.00 |
| Dec 31, 2014 | 115,775.00 |
| Sep 30, 2014 | 218,373.00 |
| Jun 30, 2014 | 182,762.00 |
| Mar 31, 2014 | 245,737.00 |
| Nov 30, 2013 | 4,597.00 |
| Aug 31, 2013 | 10,501.00 |
| May 31, 2013 | 29,098.00 |
| Feb 28, 2013 | 43,368.00 |
| Nov 30, 2012 | 132,072.00 |
| Aug 31, 2012 | 99,108.00 |
| May 31, 2012 | 72,468.00 |
| Feb 29, 2012 | 36,039.00 |